Clement Ip

Clement Ip

Auto-generated profile, based on publicly available information

Clement Ip

Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY 14263

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2000 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
CIClement Ip
Clement Ip
Marc BirringerMarc Birringer
Marc Birringer
EBEric Block
Eric Block
MKMihály Kotrebai
Mihály Kotrebai
JTJulian F. Tyson
Julian F. Tyson
DLDonald J. Lisk
Donald J. Lisk

1 December 2002 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
CIClement Ip
Clement Ip
YDYan Dong
Yan Dong
HGHoward E. Ganther
Howard E. Ganther

1 September 2003 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
BCBenjamin A. Corl
Benjamin A. Corl
DBDavid M. Barbano
David M. Barbano
DBDale E. Bauman
Dale E. Bauman
CIClement Ip
Clement Ip
The present study was designed to examine the effects of increasing dietary levels of vaccenic acid (VA) and cis-9, trans-11 conjugated linoleic acid (CLA) on chemically induced mammary carcinogenesis in rats. Both fatty acids were provided as a natural component in butter fat. The conversion of VA to CLA by Δ9-desaturase was documented previously in several species, including rats and humans. Specifically, our objective was to determine the relative contribution of dietary VA and CLA to the tissue concentration of CLA and its ability to inhibit the development of mammary carcinomas. A total of 7 diets were formulated with varying levels of CLA and VA. The overall dietary treatment scheme was designed to evaluate the modulation of mammary cancer risk by 1) small increases of CLA in the presence of a low level of VA and 2) more substantial increases of VA against a background of low levels of CLA. As expected, small increases in dietary CLA at the low end of the CLA dose-response range did not reduce tumorigenesis. In contrast, there was a distinct and marked inhibitory response to VA that was dose dependent. The effect of VA was magnified in this experiment because the dose range of VA tested was much broader than that of CLA. Fatty acid analysis showed that the conversion of dietary VA to CLA resulted in a dose-dependent increase in the accumulation of CLA in the mammary fat pad, which was accompanied by a parallel decrease in tumor formation in the mammary gland. The finding confirms that the conversion of VA to CLA is as important for cancer prevention as the dietary supply of CLA. Thus, VA is also anticarcinogenic, and VA and CLA represent functional food components that are present in ruminant fat.

1 May 2002 in Nutrition and Cancer
Verified
Journal Article
Closed access
CIClement Ip
Clement Ip
YDYan Dong
Yan Dong
MIMargot M. Ip
Margot M. Ip
SBSebastiano Banni
Sebastiano Banni
GCGianfranca Carta
Gianfranca Carta
ASAsgeir Saebo
Asgeir Saebo
There is increasing evidence that individual isomers of conjugated linoleic acid (CLA) may have unique biological or biochemical effects. A primary objective of this study was to determine whether there might be differences in the anticancer activity of 9,11-CLA and 10,12-CLA. This was achieved by evaluating the reduction in premalignant lesions and carcinomas in the mammary gland of rats that had been treated with a single dose of methylnitrosourea and given 0.5% of either highly purified CLA isomer in the diet. Our results showed that the anticancer efficacies of the two isomers were very similar. At 6 wk after carcinogen administration, the total number of premalignant lesions was reduced by 33-36%. At 24 wk, the total number of mammary carcinomas was reduced by 35-40%. The concentration of each CLA isomer and its respective metabolites was analyzed in the mammary fat pad. Tissue level of 10,12-CLA was much lower than that of 9,11-CLA. The pool of metabolites from each isomer was very similar between t...

1 March 2007 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
SLSong Li
Song Li
YZYunfei Zhou
Yunfei Zhou
RWRuiwen Wang
Ruiwen Wang
HZHaitao Zhang
Haitao Zhang
YDYan Dong
Yan Dong
CIClement Ip
Clement Ip
Doxorubicin is an effective drug against breast cancer. However, the favorable therapeutic response to doxorubicin is often associated with severe toxicity. The present research was aimed at developing a strategy of increasing doxorubicin sensitivity so that lower doses may be used without compromising efficacy. The MCF-7 human breast cancer cell line currently in use in our laboratory did not respond to doxorubicin cell killing during a 24-h treatment period. By combining doxorubicin with selenium, we were successful in producing a brisk enhancement of apoptosis. We examined the effects of these two agents on Akt activation and found that selenium was capable of depressing doxorubicin-induced Akt phosphorylation. Several lines of evidence converged to support the notion that this effect is important in mediating the synergy between selenium and doxorubicin. Selenium was no longer able to sensitize cells to doxorubicin under a condition in which Akt was constitutively activated. Increased Akt phosphorylation following treatment with doxorubicin was accompanied by increased phosphorylation of glycogen synthase kinase 3β (GSK3β) and FOXO3A, which are substrates of Akt (both GSK3β and FOXO3A lose their proapoptotic activities when they are phosphorylated). Selenium reduced the abundance of phospho-GSK3β induced by doxorubicin, whereas chemical inhibition of GSK3β activity muted the apoptotic response to the selenium/doxorubicin combination. Additional experiments showed that selenium increased the transactivation activity of FOXO3A, as evidenced by a reporter gene assay, as well as by the elevated expression of Bim (a target gene of FOXO3A). The functional significance of Bim was confirmed by the observation that RNA interference of Bim markedly reduced the potency of selenium/doxorubicin to induce apoptosis. [Mol Cancer Ther 2007;6(3):OF1–8

1 October 2005 in Cancer Research
Verified
Journal Article
Open access
PDF file
YWYue Wu
Yue Wu
HZHaitao Zhang
Haitao Zhang
YDYan Dong
Yan Dong
YPYoung-Mee Park
Young-Mee Park
CIClement Ip
Clement Ip
A monomethylated selenium metabolite, called methylseleninic acid (MSA), has recently been shown to cause global thiol redox modification of proteins. These changes represent a form of cellular stress due to protein misfolding or unfolding. An accumulation of aberrantly folded proteins in the endoplasmic reticulum (ER) triggers a defined set of transducers to correct the defects or commit the cells to apoptosis if the rescue effort is exhausted. Treatment of PC-3 human prostate cancer cells with MSA was found to induce a number of signature ER stress markers: (a) the survival/rescue molecules such as phosphorylated protein kinase–like ER-resident kinase (phospho-PERK), phosphorylated eukaryotic initiation factor-2α (phospho-eIF2α), glucose-regulated protein (GRP)-78, and GRP94; and (b) the apoptotic molecules such as caspase-12, caspase-7, and CAAT/enhancer binding protein homologous protein or growth arrest DNA damage-inducible gene 153 (CHOP/GADD153). Additional evidence suggested that CHOP/GADD153 might be an important transcription factor in apoptosis induction by MSA. In general, a higher concentration of MSA was required to elicit the apoptotic markers compared with the rescue markers. The apoptotic markers increased proportionally with the dose of MSA, whereas the rescue markers failed to keep pace with the increasing challenge from MSA. GRP78 is the rheostat of the ER stress transducers. In GRP78-overexpressing cells, the ability of MSA to up-regulate phospho-PERK, phospho-eIF2α, GRP94, caspase-12, caspase-7, and CHOP/GADD153 was significantly muted. A generous supply of GRP78 would allow cells to cope better with ER stress, thereby improving the odds for survival and negating the commitment to apoptotic death. The present study thus provides strong evidence to support an important role of ER stress response in mediating the anticancer effect of selenium.